Endologix, maker of minimally invasive devices to treat vascular diseases, has rebranded as Rhevera Medical. In a news release posted yesterday, the Santa Rosa, California–based company said the name combines "rheo," Greek for flow, and "vera," Latin for true. According to the company, the name expresses its tech focus on providing true, … [Read more...] about Endologix is now Rhevera Medical
Endologix
Endologix acquires Pounce thrombectomy system from Surmodics
Endologix announced today that it acquired the Pounce thrombectomy system from Surmodics, closing the deal on May 18. Pounce, an FDA-cleared and commercially available fully mechanical thrombectomy platform, offers the non-surgical removal of thrombi and emboli from peripheral arteries. It comes in multiple configurations to support use across a … [Read more...] about Endologix acquires Pounce thrombectomy system from Surmodics
Endologix picks former Medtronic executive as new CEO
Endologix announced today that President and CEO Dr. Matt Thompson intends to step down and take on a new role. Thompson plans to transition into the position of EVP and chief medical officer. As a result, the company appointed Dr. John Liddicoat as its new president and CEO, effective immediately. Richard Mott, Endologix's board chair, said … [Read more...] about Endologix picks former Medtronic executive as new CEO
Endologix reports positive 3-year Detour PAD treatment data
Endologix announced the final 36-month results for the DETOUR2 study evaluating its Detour system for treating peripheral arterial disease (PAD). Detour features the EndoCross device and Torus stent grafts. It enables physicians to bypass lesions in the superficial femoral artery by using stents routed through the femoral vein. This restores … [Read more...] about Endologix reports positive 3-year Detour PAD treatment data
Endologix AFX2 system wins FDA approval for PMA supplement
Endologix today announced it received FDA approval for a pre-market approval supplement relating to its AFX2 system. The expanded approval includes an updated warning and the most contemporary clinical information in the labeling for the AFX2 system. Clinical data was added to the instructions for use (IFU) to include: - Final results … [Read more...] about Endologix AFX2 system wins FDA approval for PMA supplement
Endologix reports positive results from percutaneous bypass trial
Endologix announced today that 12-month results from a trial of its Detour system demonstrated a low rate of complications. Irvine, California-based Endologix's Detour 2 FDA investigational device exemption (IDE) study was designed to evaluate the safety and effectiveness of the Detour system for percutaneous bypass in the treatment of … [Read more...] about Endologix reports positive results from percutaneous bypass trial
Endologix wins FDA breakthrough nod for aneurysm sealing system
Endologix announced today that the FDA granted breakthrough device designation for its Chimney endovascular aneurysm sealing system (Chevas). Irvine, Calif.–based Endologix designed its Chevas system as an investigational endovascular abdominal aortic aneurysm (AAA) sealing therapy that combines the Nellix 3.5 endograft with parallel visceral … [Read more...] about Endologix wins FDA breakthrough nod for aneurysm sealing system
Endologix launches Alto abdominal stent graft in Canada
Endologix (NSDQ:ELGX) today said it launched its Alto abdominal stent graft in Canada following its recent Health Canada approval. The Alto abdominal stent graft system is a polymer-based therapy for abdominal aortic aneurysm (AAA) patients. It uses a low-profile delivery system with a conformable sealing ring that molds in-situ to the patient's … [Read more...] about Endologix launches Alto abdominal stent graft in Canada
Endologix acquires PQ Bypass
Endologix today announced that it has completed its acquisition of PQ Bypass for an undisclosed amount. PQ Bypass makes the Detour platform that is designed for percutaneous femoral-popliteal bypass, which has been designated as a breakthrough device by the FDA. The Detour system has the company’s Torus stent graft and the PQ crossing device. … [Read more...] about Endologix acquires PQ Bypass
FDA committee to examine safety of endovascular stent grafts
FDA’s CDRH Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet later this year to examine the safety of endovascular stent grafts made by Endologix and other companies. Day one of the meeting will examine the benefit-risk profile of the Endologix AFX endovascular graft system regarding a potentially … [Read more...] about FDA committee to examine safety of endovascular stent grafts
